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Background: Chronic kidney disease (CKD) and diabetes are the major causes of death and disability worldwide. They are
associated with high health service utilization persisting over many years. Their slow progression and wide clinical variation
make them eminently suitable for study in population-based cohorts. However, current understanding of their prevalence, incidence,
and progression is largely based on studies conducted in clinical populations.
Objective: This study aims to establish a novel link between an existing population-based cohort (the 45 and Up Study) and
routinely collected laboratory and administrative data to facilitate research across the full disease spectrum of CKD and diabetes.
Methods: In the EXTEND45 Study (EXamining OuTcomEs in chroNic Disease in the 45 and Up Study), baseline questionnaire
responses of over 260,000 participants of the 45 and Up Study aged ≥45 years living in New South Wales (NSW), collected
between January 2006 and December 2009, are linked to data from laboratory service providers as well as national- and state-based
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administrative datasets via probabilistic linkage. Routinely collected data were obtained for participants who could be linked
between January 2005 and July 2013. Laboratory data will enable the identification of early cases of chronic disease and the
assessment of clinically relevant biochemical targets during the disease course. Health administrative datasets will allow for the
examination of health service use, pharmacological management, and clinical outcomes.
Results: The study received ethics approval from the NSW Population and Health Services Research Ethics Committee in
February 2014. Data linkage for 267,153 of the 45 and Up Study participants was completed in June 2016, with congruent linkage
achieved for 265,086 (99.23%) individuals. To date, the CKD and diabetes cohorts have been identified (published elsewhere),
and a diverse portfolio of research projects relating to disease burden, risk factors, health outcomes, and health service utilization
is in development.
Conclusions: The EXTEND45 Study represents an unparalleled opportunity to perform extensive research into diseases of
considerable public health and clinical importance. Strengths include the population-based nature of the cohort and the availability
of longitudinal information on the complete disease pathway for affected individuals.
International Registered Report Identifier (IRRID): RR1-10.2196/15646
(JMIR Res Protoc 2020;9(4):e15646)  doi: 10.2196/15646
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Introduction
Chronic diseases such as chronic kidney disease (CKD) and
diabetes are major drivers of death [1], disability [2], and health
care costs globally [3-5]. In Australia, 1.7 million people had
indicators of CKD based on biomedical testing in 2011-2012
[6], whereas recent estimates for diabetes suggest that 1.2
million individuals were living with type 1 or 2 diabetes in
2017-2018 [7]. Adults aged 65 years and older bear the majority
of this burden. Estimates vary according to study context and
design, but most studies indicate at least a twofold increase in
the prevalence of diabetes or CKD in people aged >65 years
compared with their younger counterparts [8-11]. As the
population ages, this problem is expected to further increase
[12], with important consequences for already stretched health
systems.
Diabetes and CKD are intrinsically linked [13,14], with diabetes
being an important risk factor for CKD, and both independently
associated with an increased risk of cardiovascular disease
(CVD) [15]. The relative risk of CVD in adults with diabetes
compared with those without ranges from 1 to 3 in men and 2
to 5 in women [16]. Similarly, individuals with impaired kidney
function and increased urinary albumin excretion have a twofold
to fourfold higher risk of developing CVD than those whose
kidney function is normal [17]. In patients with established
CVD, coexisting diabetes or CKD is associated with worse
outcomes and a higher mortality rate [18-20]. Early detection
and timely intervention are, therefore, paramount to the
prevention and management of this trifecta of conditions.
Although there is a growing understanding of the prevalence
and progression of diabetes, CKD, and their CVD-related
complications, many studies to date have taken place in clinical
populations recruited through specialist clinics and hospital
settings. Evidence for effective management strategies, including
clinical targets (eg, for glycated hemoglobin [HbA1c] in diabetes)
and different therapy options (eg, renin-angiotensin-aldosterone
blockade in CKD), largely stems from randomized trials
conducted in controlled clinical settings with narrowly selected
patient populations. However, the slowly progressive nature of
diabetes and CKD, coupled with their wide clinical variation,
means that earlier or milder stages of disease are missed in
hospital- or clinic-based cohorts. More population-based
research into these diseases is needed to (1) gain detailed
knowledge of the incidence and prevalence of diabetes and CKD
in the community, including earlier disease stages, (2) identify
novel determinants of disease progression, (3) better assess the
broad-scale benefits and adverse effects of evidence-based
therapies, and (4) evaluate health care utilization, costs, and
outcomes across the full disease spectrum.
Direct assessment of the various facets of chronic disease burden
and management in prospective cohorts is a major undertaking.
To generate reliable, generalizable estimates, cohort studies
must include a sufficiently large sample to capture most cases
and be adequately distributed, both geographically and
socioeconomically. In addition, rigorous follow-up of study
participants is necessary, which is costly and often results in
high loss to follow up. Routinely collected and administrative
clinical data—collected as a by-product of patient care—offer
an alternative method for acquiring detailed longitudinal
information on health service use, disease burden, and clinical
outcomes in a large proportion of the population.
The 45 and Up Study is a large-scale study established in 2006
that combines the merits of a prospective population-based
cohort study and linked administrative health data [21].
Comprising more than 260,000 individuals aged ≥45 years living
in New South Wales (NSW), the 45 and Up Study was designed
to obtain information on healthy aging through questionnaires
delivered to participants. In addition, participants consented to
their questionnaire responses being linked to routinely collected
health data for research.
The infrastructure generated through the 45 and Up Study offers
the unique opportunity to examine diabetes, CKD, and their
associated health outcomes in the community. However, to date,
there has been no effort to utilize valuable data generated from
routine laboratory testing to examine early disease states or
assess the achievement of clinical targets in patients with CKD,
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diabetes, or both. The EXTEND45 Study (EXamining
ouTcomEs in chroNic Disease in the 45 and Up Study) builds
upon the 45 and Up Study by establishing a novel link between
the 45 and Up Study participants and their clinical data held by
laboratory service providers. The EXTEND45 Study will
concurrently link the 45 and Up Study participants to a range
of other administrative datasets to obtain information across the
full spectrum of disease and health service provision, spanning
10 years.
The mission of the EXTEND45 Study is to establish a rich data
resource to examine CKD, diabetes, and their CVD-related
complications. Initial research objectives of the EXTEND45
Study include the following:
1. To determine the prevalence and incidence of CKD in the
45 and Up Study cohort and define a seminal CKD cohort
that can be used in future studies;
2. To determine the prevalence and incidence of diabetes in
the 45 and Up Study cohort and define a seminal diabetes
cohort that can be used in future studies;
3. To determine the prevalence and incidence of CKD in
individuals identified as having diabetes in the 45 and Up
Study cohort;
4. To identify risk factors for CKD and diabetes in the
community;
5. To examine the real-world management of these diseases,
including prescribing patterns, and identify
evidence-practice gaps in the care of individuals with CKD,
diabetes, or both, particularly in relation to CVD prevention;
and
6. To evaluate the attainment of clinical targets in the
community, identify risk factors for nonattainment, and
assess associated health outcomes.
This paper provides a detailed description of the data sources,
linkage methods, and governance structure of the EXTEND45
Study.
Methods
The Australian Health System
Australia has a universal health system comprising a
multifaceted network of government (public) and private
providers. Medicare is the universal public health insurance
scheme, which is funded by the federal government through a
combination of general tax revenue and a Medicare levy based
on taxable income. It is administered by Services Australia
(formerly the Department of Human Services) and provides
free or subsidized access to 3 main areas of health care
provision: (1) medical and health services outside of the public
hospital setting (administered through the Medicare Benefits
Schedule [MBS]), (2) prescription pharmaceuticals
(administered through the Pharmaceutical Benefits Scheme
[PBS]), and (3) public hospital services (funded jointly with,
and managed by, state and territory governments). In addition,
the federal government pays 75% of the fee for services and
procedures for private patients in public or private hospitals and
subsidizes private health insurance. The EXTEND45 Study
includes administrative data collected by the federal government
(ie, MBS and PBS) as well as state-specific data collections of
the NSW government.
The 45 and Up Study
Details of the 45 and Up Study have been published previously
[21]. Briefly, the 45 and Up Study comprises adults aged ≥45
years sampled from the general population of NSW, Australia’s
most populous state. Between January 2006 and December
2009, participants were randomly sampled from the Services
Australia enrollment database, with individuals aged ≥80 years
or living in remote areas oversampled by a factor of 2.
Consenting participants self-completed baseline questionnaires
in English, which included questions on demographic and
socioeconomic characteristics, personal health behaviors,
medical and surgical history, medications, and physical and
psychological health [22]. Participants also consented to
long-term follow-up, including linkage of their baseline
responses to routinely collected health datasets. In the
EXTEND45 Study, laboratory and administrative datasets have
been linked at an individual level to the 45 and Up Study
participants and their baseline questionnaire responses.
Linked Data Sources
Laboratory Service Providers
Government datasets hold information on referrals for
community laboratory services but not the clinical results of
those services. Instead, these are held by the laboratory service
providers who conduct the tests, together with patient identifiers,
tests performed, and date of testing (Figure 1). Multiple public
and private laboratory service providers are active within NSW,
and these vary in geographical scope and population coverage.
In addition, providers offer varying levels of access to
community, outpatient, or inpatient laboratory services, thereby
capturing health information across different facets of an
individual’s health journey. Several major community laboratory
service providers have been recruited for the EXTEND45 Study,
and processes are underway to include data from an inpatient
provider.
Available laboratory results and their meta-data between January
2005 and October 2015 are included at present. These enable
early case identification (eg, serum creatinine measurements
for kidney disease) as well as the assessment of disease
progression, presence of disease complications (eg, albuminuria
in patients with diabetes), and achievement of therapeutic targets
(eg, HbA1C in patients with diabetes and hemoglobin levels in
patients with CKD).
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Figure 1. An overview of the EXTEND45 Study (EXamining OuTcomEs in chroNic Disease in the 45 and Up Study) data sources and variables.
NSW: New South Wales.
New South Wales Admitted Patient Data Collection
The NSW Admitted Patient Data Collection (NSW APDC)
collates information on all admitted patient services provided
by public (including psychiatric) and private hospitals, private
day procedures centers, and public multipurpose services in
NSW [23]. For public hospitals, data are recorded for each
episode of care, with each episode defined as a period of stay
in hospital before the patient is discharged or transferred, dies,
or becomes a different type of patient (eg, acute, palliative, and
rehabilitative). For private hospitals, each APDC record
represents a complete hospital stay. Data include dates of
admission and separation, referral source, diagnoses (including
external causes), procedures, and service referred to on
discharge. Up to 50 relevant diagnoses are included and are
coded according to standardized codes from the International
Statistical Classification of Diseases and Related Health
Problems, Tenth Revision, Australian Modification
(ICD-10-AM).
At present, the EXTEND45 Study includes APDC data on
separations that occurred between January 2005 and June 2014.
NSW APDC data will be used to assess health service
utilization, length of stay, referral and transfer patterns, and
costs of hospital care (Figure 1).
Medicare Benefits Schedule and Pharmaceutical
Benefits Scheme
Medicare operates by paying a specified benefit (in the form of
a rebate) for services or prescription medicines that qualify for
a benefit under the MBS and PBS, respectively, and for which
a claim has been processed. As such, the MBS data collection
contains information on all claims for medical and diagnostic
services (including laboratory testing) provided to Australian
citizens and permanent residents by registered medical and other
practitioners, whereas the PBS data collection records all claims
for prescription medicines above the PBS copayment threshold.
From April 2012, suppliers of PBS medicines were required to
provide data on the dispensing of medicines below the
copayment threshold. MBS services and PBS items are coded
using a system of item numbers listed in the relevant schedules.
MBS and PBS data are available from June 2004 to December
2016. MBS data will be used to assess health service utilization
in primary care and outpatient settings, costs of care, and referral
patterns. PBS data will be used to examine medication
adherence, persistence, and cost, as well as the geographical
distribution of services.
New South Wales Registry of Births, Deaths, and
Marriages
All deaths are certified by a medical practitioner and registered
by the NSW Registry of Births, Deaths, and Marriages (NSW
RBDM). Details include cause and date of death, with cause of
death coded using the ICD-10-AM coding system.
Data are available from February 2006 to March 2015. Access
to NSW RBDM data will allow the comprehensive assessment
of mortality, including primary and secondary causes of death.
Australian and New Zealand Dialysis and Transplant
Registry
The Australian and New Zealand Dialysis and Transplant
(ANZDATA) Registry maintains records of all patients in
Australia and New Zealand with end-stage kidney disease who
receive chronic renal replacement therapy (RRT), that is, dialysis
or transplantation. The registry records the date of referral, start
date of RRT, treatment modalities and vascular access for
dialysis (both initial and any changes), and treatment outcomes
for all patients.
Linkage to the ANZDATA Registry will capture information
pertaining to the progression of kidney disease, including
dialysis initiation or kidney transplantation. In addition, linkage
of practice factors, such as treatment modalities and vascular
access, to information on participant socioeconomic status and
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health service use may help to identify novel areas for
intervention (Figure 1).
New South Wales Central Cancer Registry
The NSW Central Cancer Registry (NSW CCR) is a registry
of all patients with cancer in NSW. The data collected relates
to invasive primary cancers and cancer deaths. It does not
include skin cancers other than melanoma (eg, basal cell
carcinoma and squamous cell carcinoma are excluded). Data
collected by the NSW CCR includes clinical details describing
the cancer, records of care from a notifier, pathology reports,
and death certificates.
The inclusion of cancer registry data will allow further
delineation of chronic disease groups at risk of cancer
complications, with respect to comorbidities, lifestyle,
socioeconomic status, and health service utilization.
Data Linkage Methods
Record linkage brings together information on the same
individual from different data sources. Strict privacy protecting
protocols are mandated by the NSW Population and Health
Services Research Ethics Committee (PHSREC), the data
custodians, and the NSW Center for Health Record Linkage
(CHeReL). The CHeReL is an intermediate body established
in 2006 to provide expertise in data linkage methodology and
maintain a record linkage system that protects data privacy. It
is jointly managed by the NSW Ministry of Health and the NSW
Cancer Institute.
The Sax Institute has an ongoing link with Services Australia,
and as a result has processes in place to deterministically link
MBS and PBS data to their 45 and Up Study participants once
a year. This is done using a unique identifier provided to the
Sax Institute by Services Australia. For all other aforementioned
datasets, linkage to 45 and Up Study data is performed by the
CHeReL using probabilistic linkage (Figures 2 and 3). Data
custodians provide the CHeReL with an encrypted unique
identifier and relevant personal information (full name, date of
birth, address, gender, and, where available, country of birth)
for all patients over the relevant time-period. No clinical data
are provided to the CHeReL at any point in the linkage process.
The CHeReL uses personal information to link records from
different data sources, using probabilistic linkage in the
ChoiceMaker software (ChoiceMaker Technologies, Inc; Figure
2). For records with doubtful matches, a clerical review is also
conducted [24]. Once records are linked, the corresponding
individual is allocated a project-specific person number (PPN).
The CHeReL sends the PPNs for all individuals to each data
custodian, together with the original unique identifier used in
that custodian’s particular dataset (Figure 3). Each data
custodian will now hold an EXTEND45-specific PPN for each
individual in their respective dataset for whom linkage with at
least one other dataset was achieved. The data custodian merges
the PPN with the clinical variables that have been approved for
use in the EXTEND45 Study and uploads the deidentified data
to a highly secure server that is accessed by the
EXTEND45-approved researchers. The PPN is used to combine
records for the same person from different datasets.
Figure 2. A schematic diagram of the linkage process: Stage 1. Each data custodian provides the Centre for Health Record Linkage (CHeReL, a data
linkage unit) with relevant personal information of individuals who have accessed their service, together with their unique record number. The names
and details used in the figure are fictitious and do not relate to any participants of the 45 and Up Study. The CHeReL uses an algorithm to match
individuals to participants of the 45 and Up Study and assigns a project-specific person number to each individual. DOB: date of birth.
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Figure 3. A schematic diagram of the linkage process: Stage 2. The Centre for Health Record Linkage (CHeReL) provides data custodians with the
project-specific person number (PPN) for each individual, with all personal information removed. Data custodians use the PPN, together with their own
record numbers, to extract the requested data and upload the data to Secure Unified Research Environment.
Ascertainment of Disease Status
The 2 initial diseases of interest are CKD and diabetes. For each
individual, their diabetes and CKD status and, where
appropriate, timing of incident disease, are determined using
the various linked datasets. The precise methods used to
ascertain disease status will be outlined in the relevant
publications. In general, however, kidney function and CKD
status are predominantly derived using data from laboratory
records and, where appropriate, the ANZDATA Registry.
Linked serum creatinine measurements are applied to the
Chronic Kidney Disease Epidemiology Collaboration equation
to calculate the estimated glomerular filtration rate [25]. Other
available laboratory data related to kidney function include urine
albumin-to-creatinine ratio and urine protein-to-creatinine ratio.
Diabetes status is derived using the following criteria: (1)
recorded dispensing of insulin (Anatomical Therapeutic
Chemical [ATC] Classification: A10A) or oral blood
glucose-lowering medication (ATC Classification: A10B) in
the PBS dataset, (2) self-reported diabetes on the 45 and Up
Study (answered Yes to Q24. Has a doctor EVER told you that
you have diabetes?), (3) laboratory record of HbA1c result >6.5%
on one occasion, (4) laboratory record of fasting plasma glucose
levels >7.0 mmol/L, and (5) laboratory record of serum glucose
levels >11.1 mmol/L. At present, no distinction has been made
between type 1 and type 2 diabetes.
Study Governance
The EXTEND45 Study is led by a collaborative group of
physicians, epidemiologists, and statisticians coordinated by
The George Institute for Global Health, Sydney. Similar to the
45 and Up Study, the EXTEND45 Study has been designed to
facilitate cooperative projects that lie within its scope, with
oversight provided by a designated steering committee. The
steering committee includes representatives from The George
Institute for Global Health, the Universities of NSW and Sydney,
the Sax Institute, clinical experts from Australian hospitals, and
nonvoting representatives from pharmaceutical sponsors.
Current steering committee members are listed in Multimedia
Appendix 1.
The steering committee is responsible for the general oversight
and governance of the study and provides academic
independence and integrity. It provides scientific advice
regarding all aspects of study design, conduct, analyses, and
publication of results. In addition, the steering committee is
responsible for the approval of prespecified analysis plans.
Analysis proposals from internal or external researchers are
encouraged and may be submitted by academic investigators,
health service providers, or commercial health care entities.
Ethical Considerations and Data Privacy
Data collection for the EXTEND45 Study was through data
linkage only. Participants are included on the basis of their
participation and consent to the 45 and Up Study, which
included consent for linkage to their routinely-collected health
records. The 45 and Up Study was approved by the University
of NSW Human Research Ethics Committee (UNSW HREC).
Ethical approval for the EXTEND45 Study was obtained from
the NSW Population and Health Service Research Ethics
Committee (HREC/13/CIPHS/69).
Participant confidentiality is protected in several ways. First,
linkage methodology splits the processes of record linkage and
data analysis, ensuring that participant identifiers are always
kept separate from clinical data. Second, security measures in
place at the CHeReL ensure that the risks of a breach of privacy
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are minimal. Third, as mandated by the Sax Institute, all data
within the EXTEND45 Study is transferred and accessed via
the Secure Unified Research Environment (SURE). SURE is a
high-performance remote-access virtual computing environment
designed specifically for secure access, storage, and analysis of
anonymized health information [26]. To prevent data from being
exchanged between different linked data studies, each study in
the SURE facility exists within its own security perimeter.
Results
The 45 and Up Study cohort is relatively heterogeneous, with
variation observed across most variables [27]. Of the 267,153
participants of the 45 and Up Study who completed the baseline
questionnaire, data linkage was performed for 266,969 (99.93%).
Incongruent dates, for example, between the 45 and Up Study
enrollment and recorded date of death, or other erroneous dates
were identified for 1883 individuals. The final linked dataset,
therefore, comprises 265,086 individuals. As of November 2019,
laboratory data are available for 152,169 (57.40%) individuals,
with plans for expansion ongoing. Prevalent and incident cases
of CKD and diabetes have been identified from multiple data
sources, and the corresponding prevalence and incidence
estimates have been presented in separate publications. A diverse
portfolio of research questions relating to CKD and diabetes
and their management in the community are currently underway.
Discussion
Principal Findings
Through a novel linkage between the 45 and Up Study, various
administrative databases, and data from laboratory service
providers, the EXTEND45 Study represents a unique and rich
data resource that can be used to investigate a range of questions
relating to chronic disease. The study’s mission is to provide
much-needed evidence of the epidemiology, burden,
progression, and clinical management of chronic diseases such
as CKD and diabetes in the general Australian population and
across the full disease spectrum. Multiple projects that use this
data resource are already completed or underway.
Altogether, the datasets included in the EXTEND45 Study
provide a more complete overview of the care provided to
patients with chronic disease than is currently available. The
45 and Up Study baseline questionnaire included questions on
a range of personal health behaviors (eg, smoking, alcohol
consumption, physical activity, and sleep habits) as well as
demographic, social, and economic characteristics (eg, marital
status, country of birth, and education level). Although many
of these factors are either known or hypothesized to be important
confounders of chronic disease incidence and progression, they
are typically poorly captured in administrative datasets.
Conversely, the 45 and Up Study baseline data provide only a
single snapshot in time, are exclusively self-reported, and are
lacking in granularity. In the EXTEND45 Study, the combining
of NSW APDC and other health datasets will allow outcomes,
comorbidities, and complications of CKD and diabetes to be
examined. Moreover, laboratory data are critical for identifying
individuals at the early stages of their disease and allow more
granular assessment of the achievement (or lack thereof) of
clinical targets. Finally, the collection of postcodes of residences
and health care facilities in the various datasets will enable the
geographic evaluation of access and use of all tiers of health
services.
The effective use of routinely collected data and, in particular,
laboratory data in chronic disease research is demonstrated by
the many research and policy outputs of the ongoing Alberta
Kidney Disease Network (AKDN). The AKDN is a collaborative
research organization that holds a central repository of linked
laboratory and administrative data from Alberta, Canada [28].
Research using this repository has ranged from a comparative
risk assessment of coronary events in patients with diabetes and
CKD [20] to factors associated with RRT initiation [29]. In the
United Kingdom, the UK Biobank, established in 2006-2010,
has recruited 500,000 people aged 40 to 69 years to provide
detailed information about themselves, undergo various
measurements, provide biological samples for analysis, and
have their electronic health record data linked, to create a major
data resource. To date, 989 papers have been published that
used this resource. Similarly, the UK Clinical Practice Research
Datalink (CPRD) links general practice records to secondary
care, mortality, and other disease-specific databases. The CPRD
is an excellent example of the utility of real-world data in
generating evidence for drug safety guidance and clinical
practice in particular. Research carried out as part of the
EXTEND45 Study will complement these earlier studies.
Strengths and Limitations
A main strength of the EXTEND45 Study is the breadth and
diversity of the data held within it, allowing analyses into a
range of research questions to be conducted. Some of the
potential analyses have already been described. Importantly,
the inclusion of laboratory data allows researchers to use the
EXTEND45 Study dataset to identify earlier stages of both
diabetes and CKD and move away from reliance upon self-report
for diabetes. This will provide essential information on the
prevalence and progression of early disease in the community
as well as health care delivery to those affected with mild
disease. Indeed, previous studies have either relied on clinical
populations or used sources that only include outcome measures
such as hospitalization or mortality—in both instances, chronic
disease is identified later in its disease course. Second, multiple
data sources will be used to ascertain chronic disease status,
which will improve case identification. The relative
contributions of different data sources to the identification of
cases will be reported in the respective publications. Finally,
the combined infrastructure of the 45 and Up Study and
EXTEND45 Study offers a cheaper and more efficient
alternative to traditional longitudinal cohort studies for assessing
the incidence of disease, health outcomes, and health service
utilization in a large cohort.
There are important limitations that must be considered when
using the EXTEND45 Study database, both at the design stages
and during interpretation of results. Routinely collected and
administrative data are primarily collected for purposes other
than research. As a result, not all variables of interest will be
available all of the time. For example, within the EXTEND45
Study, there is no information on blood pressure, an important
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clinical variable in both CKD and diabetes. Depending on the
specific research question, surrogates for some of these missing
variables may be deployed. For instance, for high blood
pressure, a pharmaceutical dispensing of antihypertensive
medication or hospital admission for hypertension-related
problems may be used. A second limitation is that CKD is
primarily defined using laboratory tests. As a result, disease
identification is limited to individuals who have presented for
medical review and had laboratory tests performed. Conversely,
the absence of a linked laboratory test in the EXTEND45 Study
dataset may be due to (1) the test being performed by a
laboratory service provider not part of the EXTEND45 Study,
(2) an individual having no indication for a test (and, therefore,
healthier), or (3) an individual being indicated but not having
access to the appropriate health services. Given the
countervailing effects of these different possibilities, a
comparison of individuals with linked laboratory data to those
without linked laboratory data must be performed in individual
analyses. The use of routine laboratory results over time means
that inter- and intralaboratory variation may exist. The effects
of this are minimized through deep cleaning of the data to
identify potentially anomalous results or inconsistent
measurement units as well as detailed discussions with
laboratory service providers to construct a data dictionary that
is specific to their dataset.
Finally, the response rate for the 45 and Up Study baseline
questionnaire was 18%, which is similar to other comparable
studies. The 45 and Up Study cohort may, therefore, represent
a slightly healthier cohort than the general population, with
implications for the generalizability of findings that stem from
it. Unfortunately, most cohort studies are vulnerable to this
healthy volunteer effect. However, we believe that the use of
routinely collected data to follow up participants is an excellent
alternative to active longitudinal follow-up for minimizing this
potential bias over time. Moreover, internal comparisons within
the 45 and Up Study cohort have been shown to be generalizable
even in the presence of any selection bias [30]. Finally, although
not necessarily a limitation, it is important to remember that the
different data sources included in the EXTEND45 Study dataset
provide varying levels of population coverage; although
government datasets typically capture health service use in both
the private and public health care sector, the presence of multiple
laboratory service providers in NSW means that laboratory data
for the participants are not comprehensive over time or across
individuals.
Conclusions
The EXTEND45 Study is, to our knowledge, the first linked
data study in Australia to incorporate data from community
laboratory service providers with other administrative datasets
for chronic disease research. The study represents a unique
collaboration among academics, clinicians, primary care
researchers, data linkage experts, and laboratory service
providers to construct an invaluable data resource that can be
used to answer a range of questions relating to chronic disease.
Although CKD, diabetes, and CVD have been identified as
initial conditions to be examined, consideration of other chronic
diseases such as cancer, dyslipidemia, and musculoskeletal
conditions is also possible.
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